Previous Close | 87.74 |
Open | 88.18 |
Bid | 88.60 x 400 |
Ask | 88.71 x 400 |
Day's Range | 87.94 - 88.74 |
52 Week Range | 76.02 - 100.38 |
Volume | |
Avg. Volume | 1,325,206 |
Market Cap | 16.719B |
Beta (5Y Monthly) | 0.31 |
PE Ratio (TTM) | 101.85 |
EPS (TTM) | 0.87 |
Earnings Date | Apr 24, 2024 - Apr 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 109.48 |
Subscribe to Yahoo Finance Plus to view Fair Value for BMRN
Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024. Researchers will also present data from Phase 2 and Phase 3 studies of the medicine in children with achondroplasia, including results that demonstrate V
The company is a leader in the global achondroplasia treatment market